Introduction

This chapter discusses the latest trial updates on treatment options for chronic lymphocytic leukemia (CLL), focusing on the efficacy of novel drugs like Ibrucine and Vanetiklax. It explores their superiority over traditional chemotherapies, their potential to replace chemotherapy in frontline therapy, their positive results in salvage treatments, and the use of CAR T cells as an immune T cell therapy. The chapter also delves into the debate surrounding the order, combination, and duration of treatment with novel agents.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app